Moxetumomab Pasudotox

adc

Identifier: CI-DRUG-00000803
Entity page: /drug/moxetumomab-pasudotox ↗
Edges: 23

Neighbours: 8 cancers2 genes8 trials
Drawn: 18 of 18 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Moxetumomab Pasudotox approved for …APPROVED_FORderived1 of 1
→ approved for	Hairy Cell Leukemiahematologic_malignancy EMA (EU) · withdrawn · 2021-02-08 · Lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (HCL) after recei…	—	withdrawn	Hairy Cell Leukemia	1	Regulatory	ema	graph →
Moxetumomab Pasudotox …

Moxetumomab Pasudotox investigated for …INVESTIGATED_FOR7 of 7
→ investigated for	Neoplasmcancer_family	unknown	4	Neoplasm	1	Curated	chembl	graph →
→ investigated for	Hairy Cell Leukemiahematologic_malignancy	unknown	4	Hairy Cell Leukemia	1	Curated	chembl	graph →
→ investigated for	Acute Lymphoblastic Leukemiahematologic_malignancy	unknown	2	Acute Lymphoblastic Leukemia	1	Curated	chembl	graph →
→ investigated for	Chronic Lymphocytic Leukemiahematologic_malignancy	unknown	1	Chronic Lymphocytic Leukemia	1	Curated	chembl	graph →
→ investigated for	Lymphomacancer_family	unknown	1	Lymphoma	1	Curated	chembl	graph →
→ investigated for	Non-Hodgkin Lymphomahematologic_malignancy	unknown	1	Non-Hodgkin Lymphoma	1	Curated	chembl	graph →
→ investigated for	Leukemiacancer_family	unknown	1	Leukemia	1	Curated	chembl	graph →

Moxetumomab Pasudotox investigated for …INVESTIGATED_FOR7 of 7

→ investigated for

Neoplasmcancer_family

unknown

Neoplasm

Curated

Moxetumomab Pasudotox investigated in trials for …INVESTIGATED_IN_TRIALSderived5 of 5
→ investigated in trials for	Hairy Cell Leukemiahematologic_malignancy 3 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Hairy Cell Leukemia	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Acute Lymphoblastic Leukemiahematologic_malignancy 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Acute Lymphoblastic Leukemia	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Childhood B Acute Lymphoblastic Leukemia 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Childhood B Acute Lymphoblastic Leukemia	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Leukemiacancer_family 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Leukemia	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Lymphomacancer_family 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lymphoma	1	Observed	clinicaltrials	graph →

Moxetumomab Pasudotox studied in …STUDIED_INderived8 of 8
→ studied in	NCT03805932Phase 1 · active not recruiting Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia · 8 trials list this drug (1 active)	—	—	Hairy Cell Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT01891981Phase 1 · terminated Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL) · 8 trials list this drug (1 active)	—	—	Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT03501615approved for marketing An Early Access Programme for Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia · 8 trials list this drug (1 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT01829711Phase 3 · completed Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia · 8 trials list this drug (1 active)	—	—	Hairy Cell Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT00586924Phase 1 · completed A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia · 8 trials list this drug (1 active)	—	—	Hairy Cell Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT02227108Phase 2 · terminated Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma · 8 trials list this drug (1 active)	—	—	Childhood B Acute Lymphoblastic Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT02338050Phase 2 · terminated Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation · 8 trials list this drug (1 active)	—	—	Acute Lymphoblastic Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT00587015Phase 1 · terminated A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Non-Hodgkin's Lymphoma (NHL) · 8 trials list this drug (1 active)	—	—	Lymphoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths